Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Glenmark Pharmaceuticals
Sort By
Newest First
Sign in
1 / 1
1 / 1
Clinical Trials
Glenmark Receives Approval to Conduct Clinical Trials in India on Favipiravir Antiviral Tablets for COVID-19 Patients
Glenmark Pharmaceuticals
PR-M04-20-NI-044
Apr 30, 2020
Approval
Glenmark Receives Approval for Combination of Remogliflozin Etabonate and Metformin Hydrochloride for Adults With Type 2 Diabetes in India
Glenmark Pharmaceuticals
PR-M08-19-NI-067
Aug 23, 2019
FDA Acceptance
Glenmark Pharmaceuticals Announces FDA Acceptance of the Company's First New Drug Application for Ryaltris™ for Patients with Seasonal Allergic Rhinitis
Glenmark Pharmaceuticals
PR-M08-18-NI-060
Aug 15, 2018
Agreement
Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
Glenmark Pharmaceuticals
PR-M08-18-NI-050
Aug 13, 2018
Phase I Results
Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310
Glenmark Pharmaceuticals
PR-M07-18-NI-091
Jul 26, 2018
FDA Approval
The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals' Manufacturing Facility in Monroe, North Carolina
Glenmark Pharmaceuticals
PR-M06-18-NI-066-4095
Jun 19, 2018
Monoclonal Antibody
Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody
Glenmark Pharmaceuticals
PR-M05-18-NI-083
May 22, 2018
